Literature DB >> 27356035

Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma.

T Vermassen1, A De Meulenaere1, M Van de Walle1, Sylvie Rottey1.   

Abstract

Renal cell carcinoma (RCC) accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for RCC patients has changed tremendously. In this review, we will summarize the treatment options currently available for clear-cell localized, advanced and metastatic RCC (mRCC); as stated in the ESMO clinical practice guidelines, the EAU guidelines and the NCCN guidelines. Furthermore, we will discuss the recommended therapies in patients diagnosed with non-clear cell tumours.

Entities:  

Keywords:  Renal cell carcinoma; surgery; systemic therapy

Mesh：

Year:  2016        PMID： 27356035     DOI： 10.1080/17843286.2016.1193269

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN： 1784-3286            Impact factor:   1.264


  9 in total

1.  LINC02738 Participates in the Development of Kidney Cancer Through the miR-20b/Sox4 Axis.

Authors:  Chao Han; Bin Xu; Lin Zhou; Long Li; Chao Lu; Guo-Peng Yu; Yu-Shan Liu
Journal:  Onco Targets Ther       Date:  2020-10-09       Impact factor: 4.147

2.  Expression and prognostic significance of zinc fingers and homeoboxes family members in renal cell carcinoma.

Authors:  Ryuk-Jun Kwon; Yun Hak Kim; Dae Cheon Jeong; Myoung-Eun Han; Ji-Young Kim; Liangwen Liu; Jin-Sup Jung; Sae-Ock Oh
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

3.  Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.

Authors:  Javier Puente; Nuria Laínez; Marta Dueñas; María José Méndez-Vidal; Emilio Esteban; Daniel Castellano; Mónica Martinez-Fernández; Laura Basterretxea; María José Juan-Fita; Luis Antón; Luis León; Julio Lambea; Begoña Pérez-Valderrama; Sergio Vázquez; Cristina Suarez; Xavier Garcia Del Muro; Enrique Gallardo; José Pablo Maroto; M Luz Samaniego; Beatriz Suárez-Paniagua; Julián Sanz; Jesús M Paramio
Journal:  Oncotarget       Date:  2017-05-02

4.  Effects of LncRNA HCP5/miR-214-3p/MAPK1 Molecular Network on Renal Cell Carcinoma Cells.

Authors:  Jun-Feng Hao; Pei Chen; He-Yi Li; Ya-Jing Li; Yu-Ling Zhang
Journal:  Cancer Manag Res       Date:  2020-12-24       Impact factor: 3.989

5.  ANGPTL3 Overexpression Suppresses the Development of Oncogenic Properties in Renal Cell Carcinoma via the Wnt/β-Catenin Signaling Pathway and Predicts Good Prognosis.

Authors:  Yu-Jian Zhang; Lin Zhang; Fei Feng; Qi-Feng Cao
Journal:  Dis Markers       Date:  2021-08-24       Impact factor: 3.434

6.  Quaking I-5 protein inhibits invasion and migration of kidney renal clear cell carcinoma via inhibiting epithelial-mesenchymal transition suppression through the regulation of microRNA 200c.

Authors:  Ruili Zhang; Wenguang Wang; Ainiwaer Aimudula; Songmei Lu; Pengfei Lu; Remila Aihaiti; Yongxing Bao
Journal:  Transl Androl Urol       Date:  2021-10

7.  TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment.

Authors:  Guodong Liao; Jia Lv; Alin Ji; Shuai Meng; Chao Chen
Journal:  J Oncol       Date:  2021-09-06       Impact factor: 4.375

8.  Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.

Authors:  Bin Wang; Lixiao Liu; Jinting Wu; Xiaolu Mao; Zhen Fang; Yingyu Chen; Wenfeng Li
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

9.  Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment.

Authors:  Guodong Liao; Ping Wang; Yuyong Wang
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.